Infinity Pharmaceuticals, Inc. provided an update on MARIO-275, the Company’s randomized, placebo controlled Phase 2 study evaluating the benefit of adding eganelisib to nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced, metastatic urothelial cancer (mUC) over nivolumab monotherapy which is approved in this setting. Encouraging data including in post-CPI progression and PD-L1 low patients was presented at The Society for Immunotherapy of Cancer (SITC) in November and the San Antonio Breast Cancer Symposium (SABCS) in fourth quarter 2020. Program Updates and Guidance: MARIO-275: The MARIO-275 Independent Data Monitoring Committee (IDMC) determined that there was a favorable risk/benefit for patients after the successful implementation of a dose reduction from 40mg QD to 30mg QD to reduce the reversible liver enzyme elevations that were reported after the first scheduled MARIO-275 IDMC meeting. The company has completed the evaluation of the 49 patients enrolled in the study with encouraging safety, response rate and progression free survival (PFS) data, including in patients with low levels of PD-L1 expression. The company will be presenting the MARIO-275 data at a major medical meeting in first quarter 2021. As a result of the encouraging data, the company is planning a new registration-enabling study and will not re-open enrollment in MARIO-275. MARIO-3: Data was presented at SABCS in December which showed the benefit of adding eganelisib to standard of care Tecentriq® and Abraxane® therapy for front-line TNBC patients. Progression-free survival and updated overall response rate data for TNBC will be presented in first half and second half of 2021. Renal cell carcinoma data to be presented in first half 2022.